People with portopulmonary hypertension (PoPH), a form of pulmonary arterial hypertension (PAH) usually associated with liver disease, show lower five-year survival rates than people with other types of PAH. Common markers that help predict outcomes in other PAH forms failed to identify high-risk patients in this group, however. But PAH-targeted therapies were linked to improved […] The post PAH therapies extend survival in portopulmonary hypertension appeared first on Pulmonary Hypertensio...
